New Horizon Health Limited
諾輝健康

18 FEB 2021

Founded in 2015, New Horizon Health Limited (the “Company”) is the pioneer and leader in China’s colorectal cancer screening market, focusing on high-incidence cancer and home-based early cancer screening. The Company has a mission to advance the innovation and accelerate the adoption of cancer screening technologies in China. The Company has two commercialized medical tests for colorectal cancer screening (ColoClear® and Pupu Tube®) approved by the National Medical Products Administration of China (“NMPA”). ColoClear is the first and only cancer screening test in China approved by NMPA. In addition, the Company has two late-stage pipeline candidates for gastric and cervical cancer screening respectively. The Company holds global rights to all its marketed and pipeline products.

諾輝健康「公司」成立於2015年,專注於開發癌症的居家早篩,是中國癌症篩查市場的先行者和領導者。公司旨在推進癌症篩查技術的創新,並加速癌症篩查技術在中國的普及。公司旗下的兩款結直腸癌篩查產品(常衛清®和噗噗管®)已獲得國家藥品監督管理局的批准並正式開始商業化。常衛清®是中國首個且目前唯一一個獲得國家藥品監督管理局批准的癌症篩查產品。此外,公司擁有兩款適用於胃癌和宮頸癌篩查的在研產品管線。公司持有旗下所有已上市和管線產品的全球產權。